Polymorphism in IGFBP3 gene is associated with prostate cancer risk: an updated meta-analysis
Authors Qie Y, Nian X, Liu X, Hu H, Zhang C, Xie L, Han R, Wu C, Xu Y
Received 14 December 2015
Accepted for publication 20 May 2016
Published 7 July 2016 Volume 2016:9 Pages 4163—4171
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 5
Editor who approved publication: Professor Min Li
Yunkai Qie,1,* Xuewu Nian,2,* Xuesen Liu,1,* Hailong Hu,1 Changwen Zhang,1 Linguo Xie,1 Ruifa Han,1 Changli Wu,1 Yong Xu1
1Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, 2Department of Urology, Tianjin Nankai Hospital, Tianjin, People’s Republic of China
*These authors contributed equally to this work
Objective: Insulin-like growth factor-binding protein-3 (IGFBP3) is the major protein that binds with insulin-like growth factor-1 (IGF-1) and is considered to be involved in the development and progression of various cancers. We aimed to examine the association between prostate cancer (PCa) and the IGFBP3 gene-202A/C polymorphism.
Methods: A comprehensive search within PubMed, EMBASE, and Cochrane Library was conducted to identify all case–control studies up to October 30, 2015, for a meta-analysis. Pooled odds ratios (ORs) and the 95% confidence intervals (CIs) were calculated using the fixed or random effects model.
Results: Eighteen studies including 10,538 cases and 10,078 controls were identified. Overall, the CC genotype of IGFBP3-202A/C polymorphism was associated with increased risk of PCa in homozygote comparison (CC vs AA – OR =1.16, 95% CI: 1.08–1.25) and in recessive model (CC vs AA+AC – OR =1.11, 95% CI: 1.04–1.17). In dominant model, the CC/AC genotypes also implicated an increased risk of PCa (CC+AC vs AA – OR =1.11, 95% CI: 1.05–1.19). The C allele of IGFBP3-202A/C polymorphism was the risk allele for PCa relative to the A allele (OR =1.09, 95% CI: 1.05–1.14). Further stratification analysis revealed that the association between -202A/C polymorphism and PCa risk among Caucasians, but not in other ethnicities, was statistically significant (recessive model, OR =1.10, 95% CI: 1.02–1.19). In addition, the IGFBP3-202A/C polymorphism was associated with PCa risk in both population-based and hospital-based studies in homozygote comparison, recessive model, and allele model.
Conclusion: Our meta-analysis indicates that the IGFBP3-202A/C polymorphism is associated with the risk of PCa, particularly in Caucasians, with the C allele being the risk allele for PCa.
Keywords: IGFBP3, polymorphism, prostate cancer, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]